Teva Fails On Quillivant XR Appeal – Five Years After Winning
Remanded 2020 District Court Decision Affirmed On Appeal
Teva’s Actavis looks unlikely to be launching its proposed generic version of Tris Pharma’s Quillivant XR (methylphenidate) extended-release oral suspension soon, after a remanded district court decision that went against the firm was upheld on appeal.
You may also be interested in...
Actavis has suffered a setback in its attempts to bring a generic of Tris Pharma’s Quillivant XR (methylphenidate) extended-release suspension to market ahead of patent expiry, after a US Court of Appeals vacated and remanded a favourable district court ruling on numerous patent claims due to “inadequate fact-findings”.
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
Viatris remains committed to completing the sale of its global biosimilars unit to Biocon Biologics, while continuing efforts to generate up to $9bn in pre-tax proceeds by the end of 2023 from divestments.